Pleiotropic actions of amiodarone: Still puzzling after half a century

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 7, 2013, Pages 571-574

  Heijman, Jordi ^a   Dobrev, Dobromir ^a,b,c  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; GLUTATHIONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; SODIUM CHLORIDE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

CELL INFILTRATION; INFLAMMATION; LAPAROTOMY; LUNG PARENCHYMA; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; REVIEW; SEPSIS;

AMIODARONE; ANIMALS; LUNG; MALE; PROTECTIVE AGENTS; SEPSIS;

EID: 84879112447     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-013-0865-0     Document Type: Review

References (34)

1. Ashikaga K, Kobayashi T, Kimura M, Owada S, Sasaki S, Iwasa A, Furukawa K, Motomura S, Okumura K (2006) Effects of amiodarone on electrical and structural remodeling induced in a canine rapid pacing-induced persistent atrial fibrillation model. Eur J Pharmacol 536(1-2):148-153
2. Benaim G, Paniz Mondolfi AE (2012) The emerging role of amiodarone and dronedarone in Chagas disease. Nat Rev Cardiol 9(10):605-609
3. Billman GE, Gogelein H, Ruetten H, Wirth KJ (2012) Effects of a novel amiodarone-like compound SAR114646A on the pig atrium and susceptibility to ventricular fibrillation in dogs and pigs. Naunyn Schmiedebergs Arch Pharmacol 385(4):373-384
4. 2+ and HCN channels. Naunyn Schmiedebergs Arch Pharmacol 383(4):347-356
5. Chatterjee S, Ghosh J, Lichstein E, Aikat S, Mukherjee D (2012) Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. Am J Cardiol 110(4):607-613
6. Dobrev D, Nattel S (2010) New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 375(9721):1212-1223
7. Dobrev D, Carlsson L, Nattel S (2012) Novel molecular targets for atrial fibrillation therapy. Nat Rev Drug Discov 11(4):275-291
8. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324(12):781-788
9. Ehrlich JR, Dobrev D (2011) Atrial-selective sodium channel block by dronedarone: sufficient to terminate atrial fibrillation? Naunyn Schmiedebergs. Arch Pharmacol 384(2):109-114. doi: 10.1007/s00210-011-0647-5
10. Ezekowitz MD, Nagarakanti R, Lubinski A, Bandman O, Canafax D, Ellis DJ, Milner PG, Ziola M, Thibault B, Hohnloser SH, Investigators P (2012) A randomized trial of budiodarone in paroxysmal atrial fibrillation. J Interv Card Electrophysiol 34(1):1-9
11. Goegelein H, Gautier P, Roccon A, O'Connor S, Ruetten H (2011) Effects of the novel amiodarone-like compound SAR114646A on cardiac ion channels and ventricular arrhythmias in rats. Naunyn Schmiedebergs. Arch Pharmacol 384(3):231-244
12. Goette A, Bukowska A, Dobrev D, Pfeiffenberger J, Morawietz H, Strugala D, Wiswedel I, Rohl FW, Wolke C, Bergmann S, Bramlage P, Ravens U, Lendeckel U (2009) Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. Eur Heart J 30(11):1411-1420
13. Grossmann M, Dobrev D, Kirch W (1998) Amiodarone causes endothelium-dependent vasodilation in human hand veins in vivo. Clin Pharmacol Ther 64(3):302-311
14. Grossmann M, Dobrev D, Himmel HM, Kirch W (2000) Local venous response to N-desethylamiodarone in humans. Clin Pharmacol Ther 67(1):22-31
15. Halici Z, Dengiz GO, Odabasoglu F, Suleyman H, Cadirci E, Halici M (2007) Amiodarone has anti-inflammatory and anti-oxidative properties: an experimental study in rats with carrageenan-induced paw edema. Eur J Pharmacol 566(1-3):215-221
16. Heijman J, Voigt N, Dobrev D (2013) New directions in antiarrhythmic drug therapy for atrial fibrillation. Future Cardiol 9(1):71-88
17. Himmel HM, Dobrev D, Grossmann M, Ravens U (2000) N-desethylamiodarone modulates intracellular calcium concentration in endothelial cells. Naunyn Schmiedebergs. Arch Pharmacol 362(6):489-496
18. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Takeshita A (1999) Amiodarone protects cardiac myocytes against oxidative injury by its free radical scavenging action. Circulation 100(7):690-692
19. Ito H, Ono K, Nishio R, Sasayama S, Matsumori A (2002) Amiodarone inhibits interleukin 6 production and attenuates myocardial injury induced by viral myocarditis in mice. Cytokine 17(4):197-202
20. Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S (1997) Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure. Circulation 96(5):1386-1389
21. Nattel S (2011) Dronedarone in atrial fibrillation - Jekyll and Hyde? N Engl J Med 365(24):2321-2322
22. Oral H, Fisher SG, Fay WP, Singh SN, Fletcher RD, Morady F (1999) Effects of amiodarone on tumor necrosis factor-alpha levels in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 83(3):388-391
23. Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D, Manali ED (2010) Amiodarone: review of pulmonary effects and toxicity. Drug Saf 33(7):539-558
24. Polat B, Cadirici E, Halici Z, Bayir Y, Unal D, Bilgin BC, Yuksel TN, Vancelik S (2013) The protective effect of amiodarone in lung tissue of cecal ligation and puncture-induced septic rats: a perspective from inflammatory cytokine release and oxidative stress. Naunyn Schmiedebergs Arch Pharmacol (in press).
25. Reasor MJ, Kacew S (1996) An evaluation of possible mechanisms underlying amiodarone-induced pulmonary toxicity. Proc Soc Exp Biol Med 212(4):297-304
26. Said SM, Esperer HD, Kluba K, Genz C, Wiedemann AK, Boenigk H, Herold J, Schmeisser A, Braun-Dullaeus RC (2012) Efficacy and safety profile of dronedarone in clinical practice. Results of the Magdeburg Dronedarone Registry (MADRE study). Int J Cardiol (in press)
27. Schmidt C, Wiedmann F, Schweizer PA, Becker R, Katus HA, Thomas D (2012) Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels. Naunyn Schmiedebergs. Arch Pharmacol 385(10):1003-1016
28. Schwaiblmair M, Berghaus T, Haeckel T, Wagner T, von Scheidt W (2010) Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect? Clin Res Cardiol 99(11):693-700
29. Shinagawa K, Shiroshita-Takeshita A, Schram G, Nattel S (2003) Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone. Circulation 107(10):1440-1446
30. Singh BN (2008) Amiodarone as paradigm for developing new drugs for atrial fibrillation. J Cardiovasc Pharmacol 52(4):300-305
31. Singh BN, Vaughan Williams EM (1970) The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol 39(4):657-667
32. Tachikawa H, Kodama M, Watanabe K, Takahashi T, Ma M, Kashimura T, Ito M, Hirono S, Okura Y, Kato K, Hanawa H, Aizawa Y (2005) Amiodarone improves cardiac sympathetic nerve function to hold norepinephrine in the heart, prevents left ventricular remodeling, and improves cardiac function in rat dilated cardiomyopathy. Circulation 111(7):894-899
33. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP (1996) Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 348(9019):7-12
34. Zimetbaum P (2012) Antiarrhythmic drug therapy for atrial fibrillation. Circulation 125(2):381-389 Fibrillation